Jump to comment:
- Page navigation anchor for Reply to Morgan et al 2019 letter on: Valproate and the Pregnancy Prevention Programme: exceptional circumstancesReply to Morgan et al 2019 letter on: Valproate and the Pregnancy Prevention Programme: exceptional circumstancesWe agree that valproate carries a significant teratogenic and developmental risk, andShow More
alternatives should be used whenever possible . All peoplehave the right to full information about the benefits and risks of any treatment, including those who might become pregnant. We welcome the updated Risk Acknowledgement Form’s statement that contraceptive advice should...Competing Interests: HC reports in the last 3 years non-financial support from European Academy of Neurology; personal fees from Sage Pharmaceuticals Ltd, Eisai Europe Ltd, UCB Pharma Ltd, European Medicines Agency, from UK Epilepsy Nurse Specialist Association, non-financial support from Special Products Ltd, outside the submitted work. HA-L has been an Association of British Neurologists representative on the MHRA Valproate Stakeholders’ Network meeting (2018) and UK representative on the Sanofi European Valproate educational programme Advisory Board (2018). She holds Eisai Investigator initiated non-pharmaceutical grants (2017) and has received Honoraria for non-promotional lectures from Eisai (2017) and UCB (2016). RS is a principal stakeholder of the “SUDEP and Seizure Safety Checklist,” a developer of EpSMon. He has received institutional and research support and personal fees from LivaNova, UCB, Eisai, Veriton Pharma, Bial and Desitin outside the submitted work - Page navigation anchor for Valproate and the Pregnancy Prevention Programme: exceptional circumstancesValproate and the Pregnancy Prevention Programme: exceptional circumstancesWe are grateful to the authors for putting the spotlight on the valproate Pregnancy Prevention Programme (PPP).It is important to recall the very serious teratogenic effects of valproate.Show More
In addition to a 10% risk of major congenital malformations, 30-40% of children exposed in utero will have serious and persistent developmental disorders which impact their quality of life and their ability to lead independent lives. It is therefore vitally important thatall reasonable step... Competing Interests: None declared.